RxDoctor Payments Data

Lynn Wang, MD

Neurology · Denton, TXNPI 1912929605

Payments from drug & device makers

$12,430in general payments, 2019–2025

Across 536 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • UCB, Inc.$1K
  • Biogen$878
  • AbbVie$845
  • Lundbeck LLC$551
  • Eisai Inc.$426
  • plus $6K from 53 others

What the payments were for

  • Speaking & faculty fees$590%
  • Travel & lodging$1,89215%
  • Food & beverage$10,47984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.15$2,613
UCB, Inc.64$1,288
Biogen43$878
AbbVie(2 entities)48$845
Lundbeck LLC34$551
Eisai Inc.22$426
Teva Pharmaceuticals USA, Inc.17$404
Pfizer19$328
Lilly USA, LLC19$321
Neurocrine Biosciences, Inc.13$295
SK Life Science, Inc.13$276
EMD Serono, Inc.13$274
Novartis14$273
Amneal Pharmaceuticals LLC23$243
Jazz Pharmaceuticals Inc.10$218
Bristol Myers Squibb11$190
Acadia Pharmaceuticals Inc10$184
Adamas Pharmaceuticals, Inc.10$172
Sunovion Pharmaceuticals Inc.11$168
Sanofi10$167
Upsher-smith Laboratories LLC7$156
Greenwich Biosciences, Inc.8$154
Amgen6$143
Biohaven Pharmaceuticals, Inc.12$134
Genentech USA, Inc.6$132
Otsuka America Pharmaceutical, Inc.7$121
Acorda Therapeutics, Inc6$116
Sonex Health, Inc.1$100
Sumitomo Pharma America, Inc.5$99
Biohaven Pharmaceutical Holding Company Ltd.5$99
Kyowa Kirin, Inc.5$94
Neurelis, Inc.4$82
Avanir Pharmaceuticals, Inc.5$79
AstraZeneca3$76
MDD US Operations, LLC4$64
Grifols USA, LLC3$52
Abbott2$49
Aucta Pharmaceuticals, Inc.2$42
Mallinckrodt Enterprises LLC2$42
Medtronic(2 entities)2$39
Catalyst Pharmaceuticals, Inc.2$39
Banner Life Sciences, LLC2$38
Aquestive Therapeutics, Inc.2$36
Life Molecular Imaging Ltd1$29
ANI Pharmaceuticals, Inc.1$27
Axsome Therapeutics, Inc.1$27
Cycle Pharmaceuticals Inc1$27
Microtransponder, Inc.1$25
GE HealthCare1$23
Corium, LLC1$22
C2n Diagnostics, LLC1$21
Tersera Therapeutics LLC1$19
Zyla Life Sciences, Inc.1$18
Globus Medical1$17
Impel Pharmaceuticals Inc.1$17
Merz North America, Inc.1$17
Boston Scientific1$16
Johnson & Johnson1$15
Supernus Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,430 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$114,004
Medicare patients
456
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate24$136,535
Kesimpta PenOfatumumab12$122,298
Avonex Pen (4 Pack)Interferon Beta-1a12$96,867
UbrelvyUbrogepant37$59,377
Dimethyl Fumarate22$45,291
AptiomEslicarbazepine Acetate22$45,095
Nurtec OdtRimegepant Sulfate23$43,252
Glatiramer Acetate20$39,282
Aimovig AutoinjectorErenumab-Aooe41$33,259
Emgality PenGalcanezumab-Gnlm40$29,000
Lacosamide164$24,355
BriviactBrivaracetam12$22,998
NayzilamMidazolam12$18,386
Levetiracetam399$18,094
FycompaPerampanel11$13,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$404$136,53524 claims
AbbVieUbrelvy$845$59,37737 claims
PfizerNurtec Odt, Dilantin$328$46,48641 claims
Sunovion Pharmaceuticals Inc.Aptiom$168$45,09522 claims
UCB, Inc.Briviact, Nayzilam$1,288$41,38524 claims
Eisai Inc.Fycompa$426$13,00211 claims
Upsher-smith Laboratories LLCTopiramate$156$2,664167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →